You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
The battle for supremacy in the obesity market continues, and this week Eli Lilly played its latest card. The American pharmaceutical giant reported positive top-line results from a Phase III study with its oral GLP-1 agonist...